Loading...

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:10:01

AI News: Alameda based Infinimmune launched its...

BiotechTV - News ·

2025/06/19

Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an ideal way to engineer antibodies, and he describes why he believes the model will be successful for drug development both inside and outside of autoimmune conditions.

en-us

00:10:18

Draig Therapeutics launched from stealth today with a...

BiotechTV - News ·

2025/06/18

An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University Professors John Atack and Simon Ward. She highlights how unusual it is to have clinical proof of concept data already while raising a series A, and why she believes Draig will make a difference for patients.

en-us

00:09:21

BIO International 2025: Sweden's Alligator has a...

BiotechTV - News ·

2025/06/18

CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial design. He desribes looking for a partner, and what other cancers the therapy could have utility in. Plus, a next-generation bi-specific targeting CD40 and CEACAM5.

en-us

00:08:30

BIO International 2025: The new CEO of Sweden's Hansa...

BiotechTV - News ·

2025/06/18

Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for, and how Hansa it trying to expand on it. Plus, development work in Guillain-Barré syndrome and gene therapy.

en-us

00:09:01

BIO International 2025: Oppenheimer's Head of...

BiotechTV - News ·

2025/06/17

He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he cautions that it is very difficult to get early-stage development funded and that companies need to be creative to get phase 1 studies done.

en-us

00:10:02

BIO International 2025: Perspective Therapeutics CEO...

BiotechTV - News ·

2025/06/17

He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus, background on programs targeting MC1R, SSTR2, and FAP-α.

en-us

00:09:21

BIO International 2025: CEO Paul Hastings discusses...

BiotechTV - News ·

2025/06/17

He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs. Nkarta will share a data on everything before the end of the year.

en-us

00:08:02

BIO International 2025: Germany's Aicuris, a company...

BiotechTV - News ·

2025/06/17

CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS), partnered with Merck/MSD, and R&D products targeting HSV and BKV.

en-us

00:11:58

BIO International 2025: UroGen CEO Liz Barrett...

BiotechTV - News ·

2025/06/17

She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple transurethral resection of bladder tumor (TURBT) surgeries. Plus, the potential addressable market, and what she believes the approval means for UroGen as a company.

en-us

00:06:37

BIO International 2025: eGenesis CEO Mike Curtis...

BiotechTV - News ·

2025/06/17

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

en-us

00:14:04

BIO International 2025: Stifel's Tim Opler comments...

BiotechTV - News ·

2025/06/16

He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors. Plus, his take on the potential most favored nation policy, companies with negative enterprise values, and China competition.

en-us

00:14:02

BIO International 2025: Ocugen CEO Shankar Musunuri...

BiotechTV - News ·

2025/06/16

He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA today), and geographic atrophy.

en-us

00:16:03

EHA 2025: Arcellx CEO Rami Elghandour discusses the...

BiotechTV - News ·

2025/06/14

He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market, Carvykti. Plus learnings from year two of a physician survey, and his current take on CAR-T for autoimmune and CD123 for AML.

en-us

00:18:21

EHA 2025: The CEO of Ascentage Pharma, which had its...

BiotechTV - News ·

2025/06/14

Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a third-generation TKI, and highiglights Bcl-2 and EED.

en-us

00:13:09

EHA 2025: MaaT Pharma presented an update for its...

BiotechTV - News ·

2025/06/14

CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an EHA presentation from an early access program that is a follow-up from data we saw in ASH in December.

en-us

00:15:17

Microsoft's Chief Scientific Officer for Health and...

BiotechTV - News ·

2025/06/13

Matthew Lungren describes his belief how AI will "save time before it saves lives," and discusses how the clinical workforce is getting more used to adopting it. Plus how AI might affect cancer care and drug development R&D.

en-us

00:16:26

EHA 2025: CEO Arthur Sands discusses Nurix...

BiotechTV - News ·

2025/06/13

He discusses the P1 data presented at EHA for CLL and WM, which he says showed efficacy across mutations, durability, and clean safety. Plus, recent #AACR25 data on BTK, BRAF and Aurora A, and his toughts on STAT6, IRAK4, and other autoimmune targets.

en-us

00:15:13

EHA 2025: CEO Jonathan Dickinson discusses Innate...

BiotechTV - News ·

2025/06/13

He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the company's Nectin-4 ADC, and Monalizumab.

en-us

00:08:42

CLAIRITY BREAST, an AI platform that predicts...

BiotechTV - News ·

2025/06/12

CEO Leff Luber describes the tool, which is mean to augment a radiologist's analysis, and how its modeling algorithm takes into account pixels that may be unseen by the human eye.

en-us

00:09:23

Nucleate UK held its "The Forum" event in London -...

BiotechTV - News ·

2025/06/09

BiotechTV attended the event, and recorded comments from the Nucleate team, who describe the scale and role of Nucleate in this area. We hear about the Activator program, and meet entrepreneurs who have benefitted from it. Plus, how Nucleate has partnered with the government's Advanced Research and Invention Agency (ARIA) in the UK.

en-us

486 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

跨国串门儿计划

yikai

The Grave Talks | Haunted, Paranormal & Supernatural

Ghost Stores, Haunted, Paranormal &...

Real Ghost Stories Online

Real Ghost Stories Online | Paranormal,...

Sleep Science

Sleep Science